COBRA (Co-morbidity in Relation to HIV/AIDS)
The COBRA (Comorbidity in relation to AIDS) programme aims to further investigate whether reported comorbidities are more common and possibly occur at a younger age in people living with HIV than in HIV-negative individuals. In addition, in-depth research is being done into the various underlying mechanisms, including those associated with HIV infection and those associated with the use of antiretroviral treatment (refer to http://fp7-cobra.eu for further information).
As a COBRA partner, SHM collaborates with the AMC and provides the data collection infrastructure for monitoring the incidence and prevalence of a number of these comorbidities. The results obtained from this research may be used to inform and adapt national and international guidelines for prevention and management of comorbidities in ageing HIV-positive individuals.
COBRA’s EU funding formally ended March 1, 2017, but scientific productivity based on collected data and biomaterial will continue during the coming years.
Recent COBRA publications:
Increased brain-predicted ageing in treated HIV disease
Cole JH, Underwood J, Caan MWA, De Francesco D, van Zoest RA, Leech R, Wit FWNM, Portegies P, Geurtsen GJ, Schmand B, Schim van der Loeff MF, Franceschi C, Sabin C, Majoie BLM, Winston A, Reiss P, Sharp DJ ; COBRA collaboration.
Neurology. 2017 Apr 4;88(14):1349-1357. doi: 10.1212/WNL.0000000000003790. [Epub 2017 Mar 3]
Grey and white matter abnormalities in treated HIV-disease and their relationship to cognitive function
Underwood J, Cole JH, Caan M, De Francesco D, Leech R, van Zoest RA, Su T, Geurtsen GJ, Schmand BA, Portegies P, Prins M, Wit FW, Sabin CA, Majoie C, Reiss P, Winston A, Sharp DJ; Co-morBidity in Relation to Aids (COBRA) Collaboration.
Clin Infect Dis. 2017 Apr 6. doi: 10.1093/cid/cix301. [Epub ahead of print]
High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in cerebrospinal fluid
Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Garagnani P, Pirazzini C, Franceschi C, Fuchs D, Gisslén M, Winston A, Reiss P, Kootstra NA; Comorbidity in Relation to AIDS (COBRA) Collaboration.
Open Forum Infect Dis. 2017 May 25;4(3):ofx108. doi: 10.1093/ofid/ofx108. eCollection 2017 Summer
Epidemiology of ageing with HIV: what can we learn from cohorts?
Sabin CA, Reiss P.
AIDS. 2017 Jun 1;31 Suppl 2:S121-S128. doi: 10.1097/QAD.0000000000001374
Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls
Booiman T, Wit FW, Girigorie AF, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Franceschi C, Deeks SG, Winston A, Reiss P, Kootstra NA; Co-morBidity in Relation to Aids (COBRA) Collaboration.PLoS One. 2017 Aug 14;12(8):e0183357. doi: 10.1371/journal.pone.0183357. eCollection 2017
Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers
Van Zoest RA, Underwood J, De Francesco D, Sabin CA, Cole JH, Wit FW, Caan MWA, Kootstra NA, Fuchs D, Zetterberg H, Majoie CBLM, Portegies P, Winston A, Sharp DJ, Gisslén M1, Reiss P; Co-morBidity in Relation to AIDS (COBRA) Collaboration.
J Infect Dis. 2017 Oct 24. doi: 10.1093/infdis/jix553. [Epub ahead of print]